RNA
Atrium Therapeutics, Inc.
7.80$
-3.7%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q2 12 | Q3 12 | Q4 12 | Q1 13 | Q2 13 | Q3 13 | Q4 13 | Q1 14 | Q2 14 | Q3 14 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +108.5% | +7.9% | -5.5% | -13.2% | +38.7% | -1.8% | +468.0% | -99.2% | – | – | – | +190.2% | +122.3% | -6.0% | +13.5% | +13.3% | +22.7% | +26.2% | -3.6% | -17.0% | -14.4% | -3.1% | +21.3% | +14.0% | +11.6% | -19.4% | +3.7% | +21.7% | -22.2% | +61.6% | -42.3% | +14.2% | +27.3% | -47.1% | +144.6% | +224.3% | -93.1% | +2,185.8% | -84.7% | – | |
| – | +43.7% | +26.6% | -0.2% | +17.1% | -8.9% | +24.7% | +7.6% | +6.0% | +7.1% | -89.1% | +100.7% | +101.3% | +10.7% | -1.8% | +62.0% | +5.2% | +44.0% | +51.8% | +9.8% | +9.4% | +32.8% | -16.0% | +43.7% | -6.2% | +22.2% | +4.7% | -10.7% | +11.8% | -98.7% | +4.2% | +7.2% | +3.3% | +3.9% | – | – | – | – | -89.9% | +127.2% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | +13.5% | -600.3% | – | – | – | – | – | – | – | – | – | – | – | – | – | +83.9% | -53.2% | +72.0% | +27.3% | -47.1% | -8,636.4% | – | -93.1% | +2,168.2% | -86.3% | – | |
| – | +50.9% | +23.0% | -12.2% | +15.3% | +18.6% | +0.2% | +1.6% | +4.1% | +25.4% | -86.7% | +100.7% | +101.3% | +10.7% | -1.8% | +62.0% | +5.2% | +44.0% | +51.8% | +9.8% | +9.4% | +32.8% | -16.0% | +43.7% | -6.2% | +22.2% | +4.7% | -10.7% | +11.8% | +10.7% | +26.5% | -4.3% | +20.7% | +23.9% | +4.0% | +38.8% | +12.2% | -88.1% | -9.9% | -7.9% | – | |
| – | – | – | – | – | – | – | – | – | – | – | +75.0% | -52.6% | +144.0% | +6.3% | +48.9% | +28.4% | +28.2% | +22.2% | +6.5% | +5.5% | +12.4% | +15.3% | +1.4% | +16.2% | +2.9% | +16.2% | +1.8% | +11.8% | +17.4% | -13.8% | +49.2% | +12.3% | +21.8% | +18.6% | +9.7% | -84.3% | +426.5% | -33.4% | -49.3% | – | |
| – | – | – | – | – | – | – | – | – | – | – | +89.9% | +41.8% | +27.9% | +0.2% | +58.6% | -68.5% | +28.2% | +22.2% | +6.5% | +5.5% | +12.4% | +15.3% | +1.4% | +16.2% | +2.9% | +16.2% | +1.8% | +11.8% | +397.6% | +17.2% | +4.9% | +19.6% | +23.4% | +7.4% | -72.3% | -77.0% | +477.7% | -24.8% | -31.2% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -23.7% | -65.9% | +435.6% | +15.4% | -6.1% | -47.9% | +144.1% | -0.9% | +1.2% | +11.7% | +226.6% | +20.3% | +196.7% | -98.2% | +67.9% | -100.0% | – | -100.0% | – | – | – | +2,677.8% | +144.4% | +119.6% | +64.2% | -82.3% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | +222.9% | +20.7% | +197.8% | -101.5% | – | -114.4% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Showing the most recent 40 periods — older statements are on file for this stock.
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.